| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
490.92(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.86 - $18.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 15.9 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
371,682 |
558,056 |
762,731 |
| Total Buy Value |
$0 |
$2,488,242 |
$3,530,830 |
$5,499,522 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
10 |
14 |
17 |
| Total Shares Sold |
39,644 |
189,644 |
339,644 |
339,644 |
| Total Sell Value |
$515,799 |
$1,516,799 |
$2,312,182 |
$2,312,182 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
5 |
8 |
10 |
10 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gad Thomas |
See Remarks |
• • – |
2020-12-14 |
4 |
AS |
$52.89 |
$211,546 |
I/I |
(4,000) |
618,000 |
|
-46% |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-11 |
4 |
S |
$51.17 |
$2,558,640 |
D/D |
(50,000) |
0 |
|
47% |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-11 |
4 |
OE |
$2.00 |
$100,000 |
D/D |
50,000 |
50,000 |
|
- |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-10 |
4 |
S |
$50.75 |
$2,537,620 |
D/D |
(50,000) |
0 |
|
48% |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-10 |
4 |
OE |
$2.00 |
$100,000 |
D/D |
50,000 |
50,000 |
|
- |
|
| Rajah Vignesh |
SVP and CMO |
• – – |
2020-12-02 |
4 |
B |
$51.03 |
$11,890 |
I/I |
233 |
1,697 |
1.99 |
-47% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-12-01 |
4 |
AS |
$51.42 |
$205,685 |
I/I |
(4,000) |
622,000 |
|
-51% |
|
| Gill David N |
Director |
– • – |
2020-11-18 |
4 |
AS |
$45.77 |
$91,530 |
D/D |
(2,000) |
0 |
|
-33% |
|
| Gill David N |
Director |
– • – |
2020-11-18 |
4 |
OE |
$11.16 |
$22,320 |
D/D |
2,000 |
2,000 |
|
- |
|
| Rajah Vignesh |
SVP and CMO |
• – – |
2020-11-17 |
4 |
B |
$45.74 |
$66,963 |
I/I |
1,464 |
1,464 |
1.99 |
-35% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-11-16 |
4 |
AS |
$46.17 |
$184,672 |
I/I |
(4,000) |
626,000 |
|
-36% |
|
| Gill David N |
Director |
– • – |
2020-11-03 |
4 |
AS |
$45.00 |
$180,000 |
D/D |
(4,000) |
0 |
|
-21% |
|
| Gill David N |
Director |
– • – |
2020-11-03 |
4 |
OE |
$11.16 |
$44,640 |
D/D |
4,000 |
4,000 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-11-02 |
4 |
AS |
$43.69 |
$174,769 |
I/I |
(4,000) |
630,000 |
|
-17% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-10-15 |
4 |
AS |
$39.15 |
$156,604 |
I/I |
(4,000) |
634,000 |
|
-15% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-10-01 |
4 |
AS |
$38.88 |
$155,524 |
I/I |
(4,000) |
638,000 |
|
20% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-15 |
4 |
AS |
$40.81 |
$163,225 |
I/I |
(4,000) |
642,000 |
|
9% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-14 |
4 |
S |
$41.00 |
$925,426 |
D/D |
(22,569) |
0 |
|
-5% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-14 |
4 |
OE |
$2.00 |
$45,138 |
D/D |
22,569 |
22,569 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-11 |
4 |
S |
$40.33 |
$547,331 |
D/D |
(13,571) |
0 |
|
-13% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-11 |
4 |
OE |
$2.00 |
$27,142 |
D/D |
13,571 |
13,571 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-10 |
4 |
S |
$41.58 |
$576,360 |
D/D |
(13,860) |
0 |
|
-13% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-10 |
4 |
OE |
$2.00 |
$27,720 |
D/D |
13,860 |
13,860 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-09-01 |
4 |
AS |
$41.60 |
$166,390 |
I/I |
(4,000) |
646,000 |
|
20% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-08-17 |
4 |
AS |
$40.35 |
$161,392 |
I/I |
(4,000) |
650,000 |
|
22% |
|
249 Records found
|
|
Page 7 of 10 |
|
|
0.13 (1.07%) 
